VivoSeq
Oncology

Cancer of the Pancreas

0

Pipeline Programs↗

1

Active Trials↗

5

Companies Involved↗

Cancer of the Pancreas is an early-stage landscape with 0 programs across 5 companies. The most active players are Radiation Therapy Oncology Group, Roche, Eli Lilly.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

95/100

Attrition Rate

4/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group

0 programs

PreclinicalRoche logo

Roche

0 programs

PreclinicalEli Lilly logo

Eli Lilly

0 programs

PreclinicalDaiichi Sankyo logo

Daiichi Sankyo

0 programs

PreclinicalE

Eastern Cooperative Oncology Group

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

25

clinical trials

Completed20 · 80%
Unknown status3 · 12%
Withdrawn1 · 4%
Recruiting1 · 4%

Clinical Trials

Trial Activity

25 trials

The Cancer of the Pancreas Screening-5 CAPS5)Study
Recruiting·JJohns Hopkins University·Phase 3·NCT02000089·9,000 enrolled
Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas
Completed·National Cancer Institute (NCI)·Phase 2·NCT00085371·116 enrolled
ISIS 2503 in Treating Patients With Advanced Cancer of the Pancreas
Completed·UUniversity of Alabama at Birmingham·Phase 2·NCT00005594·4 enrolled
A Phase I Trial of Gemcitabine and Radiation in Locally Advanced Unresectable Cancer of the Pancreas
Completed·National Cancer Institute (NCI)·Phase 1·NCT00001431·20 enrolled
Combination Chemotherapy in Treating Patients With Advanced Cancer of the Pancreas
Completed·UUniversity of Southern California·Phase 2·NCT00002955·21 enrolled
Fluorouracil With or Without Cisplatin in Treating Patients With Advanced or Metastatic Cancer of the Pancreas
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00003029·200 enrolled
Gemcitabine, Herceptin and Radiation to Treat Cancer of the Pancreas
Completed·National Cancer Institute (NCI)·Phase 2·NCT00005926·50 enrolled
Combination Chemotherapy and Radiation Therapy Plus Surgery in Treating Patients With Advanced Cancer of the Pancreas
Completed·National Institutes of Health Clinical Center (CC)·Phase 2·NCT00020345
Cancer of the Pancreas Screening Study (CAPS 3)
Completed·JJohns Hopkins University·N/A·NCT00438906·200 enrolled
Gemcitabine and Radiation Therapy in Treating Patients With Cancer of the Pancreas
Completed·WWake Forest University Health Sciences·Phase 2·NCT00010166·26 enrolled
Gemcitabine and ISIS 2503 in Treating Patients With Advanced or Metastatic Cancer of the Pancreas
Completed·Alliance for Clinical Trials in Oncology·Phase 2·NCT00006467·48 enrolled
Fluorouracil, Gemcitabine, and Radiation Therapy in Treating Patients With Cancer of the Pancreas
Completed·Radiation Therapy Oncology Group logoRadiation Therapy Oncology Group·Phase 3·NCT00003216·518 enrolled
A Study On An Immunostimulant Antibody In Combination With Chemotherapy For Advanced Cancer Of The Pancreas
Completed·Roche logoRoche·Phase 1·NCT00711191·22 enrolled
Surgery Followed by Radiation Therapy and Chemotherapy in Treating Patients With Cancer of the Pancreas
Completed·MMayo Clinic·Phase 3·NCT00003049·100 enrolled
A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.
Completed·Eli Lilly logoEli Lilly·Phase 3·NCT00035035
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)